Long-circulating rabeprazole liposome composition and preparation method and application thereof

A technology of rabeprazole fat and rabeprazole, which is applied in the field of long-circulation rabeprazole liposome composition and its preparation, can solve the instability of rabeprazole oral preparations and the leakage of drug phospholipid bimolecules , particle size and distribution increase, etc., to achieve good product stability, solve thermal discoloration, and improve bioavailability

Inactive Publication Date: 2015-04-29
JIANGSU AOSAIKANG PHARMA CO LTD
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Clinically, rabeprazole has the following disadvantages: ①Rabeprazole sodium is stable under strong alkaline conditions, and its pH value is adjusted to a maximum of 12. It is beyond the tolerance range of the human body, and there is a certain safety risk; ② Rabeprazole is easily decomposed and deteriorated when exposed to light, heat, oxidation and acid, and a considerable part of it produces sulfonyl compounds (inactive ingredients). ③ Oral preparations of rabeprazole are extremely unstable under acidic conditions, and if taken directly orally, they will be degraded in gastric acid, making the bioavailability significantly lower; ④ When Rabeprazole ordinary injection is compatible with glucose solution , there will be a sauce yellow phenomenon, which proves that rabeprazole has been destroyed in large quantities, and there is a certain risk of injection
[0010] The stability of liposomes is an important issue that limits the development of liposome formulations. When freeze-drying or spray drying makes liposomes, after liposome reconstitution Its particle size is generally doubled, so it is easy to coagulate, fuse, and settle during the reconstitution process, resulting in a significant increase in particle size and distribution, and the drug is easy to leak from the phospholipid bimolecule

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-circulating rabeprazole liposome composition and preparation method and application thereof
  • Long-circulating rabeprazole liposome composition and preparation method and application thereof
  • Long-circulating rabeprazole liposome composition and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 Preparation of long-circulation rabeprazole liposome freeze-dried powder injection

[0062] Prescription: (1000 bottles)

[0063] Component Dosage

[0064] Rabeprazole 20g

[0065] Hydrogenated Soy Phosphatidylcholine 120g

[0066] Cholesterol 60g

[0067] Cultured Phosphatidylethanolamine 10g

[0068] α-Tocopherol 0.4g

[0069] Edetate Calcium Sodium 0.4g

[0070] Trehalose 60g

[0071] Preparation Process:

[0072] (1) Add 20g of rabeprazole, 120g of hydrogenated soybean phosphatidylcholine, 60g of cholesterol and 0.4g of α-tocopherol into 2000ml of ethanol, heat to 45°C, stir and disperse evenly, and filter through a 0.22μm organic membrane;

[0073] (2) Add 60g of trehalose and 0.4g of calcium sodium edetate to 2000ml of 10mmol / L phosphate buffer solution (pH = 7.0), shake and stir to dissolve, filter through a 0.22μm water membrane, and store at 45°C Lower heat preservation;

[0074] (3) Slowly add the solution prepared in step (1) into the ...

Embodiment 2

[0079] Example 2 Preparation of long-circulation rabeprazole liposome freeze-dried powder injection

[0080] Prescription: (1000 bottles)

[0081] Component Dosage

[0082] Rabeprazole 20g

[0083] Distearoylphosphatidylcholine 80g

[0084] Cholesterol 20g

[0085] Cultured Phosphatidylethanolamine 20g

[0086] α-Tocopherol 0.6g

[0087] Edetate Disodium 0.6g

[0088] Trehalose 50g

[0089] Preparation Process:

[0090] (1) Add 20g of rabeprazole, 100g of distearoylphosphatidylcholine, 40g of cholesterol and 0.6g of α-tocopherol into 1600ml of ethanol and tert-butanol solution with a volume ratio of 3:1, heat to 45°C and stir Uniform dispersion, 0.22μm organic membrane filtration;

[0091] (2) Add 50g trehalose and 0.6g edetate disodium into 1600ml citrate buffer solution (pH = 7.0) with a concentration of 10mmol / L, shake and stir to dissolve, filter through a 0.22μm water membrane, and filter at 45 Keep warm at ℃;

[0092] (3) Slowly add the solution item obtai...

Embodiment 3

[0097] Example 3 Preparation of long-circulation rabeprazole liposome freeze-dried powder injection

[0098] Prescription: (1000 bottles)

[0099] Component Dosage

[0100] Rabeprazole 20g

[0101] Dipalmitoyl Phosphatidylcholine 160g

[0102] Cholesterol 50g

[0103] Cultured Phosphatidylethanolamine 20g

[0104] α-Tocopherol 1.0g

[0105] Edetate Calcium Sodium 1g

[0106] Sucrose 20g

[0107] Preparation Process:

[0108] (1) Add 20g of rabeprazole, 130g of hydrogenated soybean phosphatidylcholine, 50g of cholesterol, 20g of cultured phosphatidylethanolamine and 0.7g of α-tocopherol into 2000ml of ethanol, heat to 45°C and stir to disperse evenly. membrane filtration;

[0109] (2) Add 60g of sucrose and 1g of calcium sodium edetate to 2000ml of 10mmol / L phosphate buffer solution (pH = 7.0), shake and stir to dissolve, filter through a 0.22μm water film, and keep warm at 45°C ;

[0110] (3) Slowly add the solution item obtained in step (1) into the solution item...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicinal preparations, specifically to a long-circulating rabeprazole liposome composition and its preparation method and application. The composition comprises rabeprazole, lecithin, cholesterol, Phosphatidylethanolamine Pegol, an antioxidant, metal chelate and a freeze-drying protective additive. The liposome injection provided by the invention has good re-dissolubility. After redissolution, particle size is uniform and stability is excellent. Quality of a preparation product is enhanced, half-life period of rabeprazole in the blood circulation system is prolonged, and bioavailability is higher.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a long-circulation rabeprazole liposome composition and its preparation method and application. Background technique [0002] Rabeprazole, chemical name: 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzo Imidazole, molecular formula: C 18 h 20 N 3 o 3 S, molecular weight: 358.44, chemical structural formula: [0003] . [0004] Rabeprazole is a derivative of benzimidazole, a new type of proton pump inhibitor, without anticholinergic and anti-H2 histamine properties, but can be attached to gastric parietal cells by inhibiting the H+ / Na+-ATPase of gastric parietal cells to reduce gastric acid secretion. This enzyme system is regarded as an acid proton pump, so rabeprazole sodium acts as a proton pump inhibitor in the stomach to block the production of gastric acid, and this effect is dose-related. Animal experiments have confirmed that rab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/127A61K9/19A61K9/20A61K31/4439A61P1/04
Inventor 陈庆财伏世建蔡继兰刘留成金雪锋
Owner JIANGSU AOSAIKANG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products